Oct 2026· Journal of Affective Disorders· pp.
122676
· 0 citations· 54 references
Medicine
TL;DR
Improvements on secondary measures suggest potential benefits for anhedonia and depression severity that warrant confirmation in larger trials.
Abstract
Background
Anhedonia is a core feature of major depressive disorder (MDD) that is frequently resistant to available treatments. Psilocybin's specific efficacy for anhedonia remains unclear.
Aims
To evaluate psilocybin's efficacy for anhedonia in treatment-resistant MDD.
Methods
In this randomized, double-blind, placebo-controlled trial, 20 participants with treatment-resistant MDD received psilocybin (25 mg or 1 mg) with psychological support. The primary outcome was change in the Dimensional Anhedonia Rating Scale (DARS) score at week 1; DARS change at week 8 was a secondary outcome. The Snaith-Hamilton Pleasure Scale (SHAPS) and Montgomery-Åsberg Depression Rating Scale (MADRS) were used as additional secondary outcome measures for anhedonia and overall depression severity, respectively.
Results
The primary outcome was not statistically significant: between-group difference in DARS change at week 1 was 11.2 (95% confidence interval [CI], -1.0 to 23.3; p = 0.073). At week 8, the secondary DARS outcome indicated greater improvement in anhedonia with 25 mg (difference, 14.7; 95% CI, 2.5 to 26.8; p = 0.018). SHAPS improvement favored 25 mg at week 1 (difference, -3.2; 95% CI, -6.1 to -0.3; p = 0.029), but not week 8 (-2.1; 95% CI, -4.9 to 0.9; p = 0.168). MADRS improvement favored 25 mg at weeks 1 (-11.9; 95% CI, -19.2 to -4.5; p = 0.002) and 8 (-11.6; 95% CI, -19.0 to -4.2; p = 0.002).
Conclusions
Psilocybin 25 mg did not significantly improve anhedonia at the primary week 1 endpoint. However, improvements on secondary measures suggest potential benefits for anhedonia and depression severity that warrant confirmation in larger trials.
CLINICAL TRIAL REGISTRATION
ClinicalTrials.govNCT06230757.
Anhedonia, a prominent symptom of major depressive disorder (MDD), severely impairs patients’ quality of life and is challenging to treat. Although esketamine has shown potential in treating anhedonia in adult treatment-resistant MDD, its effects on adolescents remain under-explored.
In this study, a prosp...
Qian-Qian Wu, Wei-Cheng Li, Zhan-Jie Luo et al.· BMC Psychiatry· 0 citations
Major depressive disorder (MDD) is one of the leading causes of disability worldwide. A substantial proportion of patients fail to achieve remission through standard monoaminergic therapies, meeting the clinical criteria for treatment-resistant depression (TRD). TRD is associated with significant clinical morbidity and...
Mateusz Gawin, Emilia Koziara, Mateusz Gadzina et al.· International Journal of Inn...· 0 citations
It is suggested that psilocybin therapy may be safe, tolerable, and preliminarily efficacious for treating depression in BD-II, but randomized controlled trials are needed to confirm efficacy and optimize protocols.
Amanda E. Downey, B. Szigeti, Ellen R. Bradley et al.· Journal of Clinical Psychiat...· 0 citations
BACKGROUND
Anhedonia is a debilitating core feature of mood disorders, and is associated with significant functional impairment and poor quality of life. Psilocybin has recently emerged as a novel antidepressant treatment in major depressive disorder (MDD), however, its effects on anhedonia specifically have yet to be...
Erica S. Kaczmarek, Sabrina Wong, Noah Chisamore et al.· Journal of Psychiatric Resea...· 0 citations
Objective: Anxious distress is associated with poor outcomes in the treatment of major depressive disorder (MDD). This exploratory post hoc analysis utilized data from a phase 3 study to investigate adjunctive lumateperone 42 mg efficacy in patients with MDD with inadequate antidepressant therapy (ADT) response and anx...
Gary S. Sachs, S. Durgam, W. Earley et al.· Journal of Clinical Psychiat...· 0 citations
Background. Change in cognitive control is a candidate transdiagnostic mechanism of psychedelic therapy. One account predicts that, once acute effects resolve, psilocybin shifts control toward flexibility while sparing inhibition and working memory. A motivational account (PRISM) predicts that psilocybin increases the...
C. Sayali, E. Weisman, F. Barrett· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.